Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mural Oncology Plc (MURA)

Mural Oncology Plc (MURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,382
  • Shares Outstanding, K 17,344
  • Annual Sales, $ 0 K
  • Annual Income, $ -128,510 K
  • EBIT $ -123 M
  • EBITDA $ -120 M
  • 60-Month Beta 2.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.64
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.92
  • Most Recent Earnings $-0.21 on 11/06/25
  • Next Earnings Date 03/10/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -2.01
  • Growth Rate Est. (year over year) +81.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.02 +0.99%
on 12/02/25
2.10 -2.86%
on 11/25/25
-0.04 (-1.92%)
since 11/04/25
3-Month
2.02 +0.99%
on 12/02/25
2.12 -3.77%
on 09/25/25
-0.03 (-1.45%)
since 09/04/25
52-Week
0.95 +114.74%
on 04/09/25
4.74 -56.96%
on 02/07/25
-1.97 (-49.13%)
since 12/04/24

Most Recent Stories

More News
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”) announces that the scheme of arrangement between Mural and its shareholders under Chapter...

XOMA : 26.37 (-8.41%)
MURA : 2.04 (unch)
Mural Oncology Announces Sanction of the Scheme by the High Court

WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement...

MURA : 2.04 (unch)
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“ Mural ”) announces that, in accordance with the terms of the transaction agreement between...

XOMA : 26.37 (-8.41%)
MURA : 2.04 (unch)
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION ...

XOMA : 26.37 (-8.41%)
MURA : 2.04 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders

NEW YORK , Sept. 29, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MURA : 2.04 (unch)
PHLT : 7.75 (+0.26%)
ARIS : 23.69 (+1.02%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - AMWD, PHLT, ARIS, and MURA

NEW YORK , Sept. 27, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered...

MURA : 2.04 (unch)
PHLT : 7.75 (+0.26%)
ARIS : 23.69 (+1.02%)
AMWD : 62.95 (-0.58%)
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”), a clinical-stage immuno-oncology company, today announces for the purposes of...

MURA : 2.04 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBAN, HBI, NWE, MURA on Behalf of Shareholders

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MURA : 2.04 (unch)
CBAN : 18.67 (-0.05%)
NWE : 68.71 (+0.39%)
HBI : 6.47 (-1.82%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - GTLS, PHLT, ARIS, and MURA

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered...

MURA : 2.04 (unch)
PHLT : 7.75 (+0.26%)
ARIS : 23.69 (+1.02%)
GTLS : 207.41 (+0.17%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders

NEW YORK , Aug. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MURA : 2.04 (unch)
NWE : 68.71 (+0.39%)
SCPH : 5.67 (unch)
BKH : 73.34 (+0.27%)

Business Summary

Mural Oncology plc is a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural Oncology...

See More

Key Turning Points

3rd Resistance Point 2.05
2nd Resistance Point 2.05
1st Resistance Point 2.04
Last Price 2.04
1st Support Level 2.03
2nd Support Level 2.03
3rd Support Level 2.02

See More

52-Week High 4.74
Fibonacci 61.8% 3.29
Fibonacci 50% 2.84
Fibonacci 38.2% 2.40
Last Price 2.04
52-Week Low 0.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar